<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10698">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02967692</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001F2301</org_study_id>
    <secondary_id>2016-002794-35</secondary_id>
    <nct_id>NCT02967692</nct_id>
  </id_info>
  <brief_title>A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a
      BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic
      BRAF V600 mutant melanoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">December 8, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 8, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Run-In (Part 1): Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Incidence of DLTs during the first 8 weeks of treatment with PDR001 in combination of dabrafenib and trametinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarker cohort (Part 2): Immune microenvironment and biomarker modulation</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in PD-L1 levels and CD8+ cells upon treatment with PDR001 in combination with dabrafenib and trametinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomized (Part 3): Progression-Free Survival (PFS), investigator assessed by RECIST 1.1</measure>
    <time_frame>Up to disease progression or death due to any cause, whichever occurs first (5 years)</time_frame>
    <description>Progression-free survival is defined as the time from the date of first dose to the date of the first documented radiological progression using RECIST 1.1 response criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to death due to any cause (5 years)</time_frame>
    <description>Overall survival is defined as the time from date of randomization to date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to disease progression or death due to any cause, whichever occurs first (5 years)</time_frame>
    <description>ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to disease progression or death due to any cause, whichever occurs first (5 years)</time_frame>
    <description>Duration of response is defined as the time from first documented response of CR or PR to date of first documented progression or death, according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to disease progression or death due to any cause, whichever occurs first (5 years)</time_frame>
    <description>Disease control rate is defined as the proportion of patients with CR or PR or subjects with SD lasting for a duration of at least 24 weeks as per local review according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global health status/quality of life score of the EORTC QLQ-C30</measure>
    <time_frame>Up to 60 days post progression (5 years)</time_frame>
    <description>Patient's health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global health status/quality of life score of the FACT-M subscale</measure>
    <time_frame>Up to 60 days post progression (5 years)</time_frame>
    <description>Patient's health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global health status/quality of life score of the EQ-5D-5L</measure>
    <time_frame>Up to 60 days post progression (5 years)</time_frame>
    <description>Patient's health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 10 point definitive deterioration in overall quality of life score from EORTC QLQ-C30</measure>
    <time_frame>Up to 60 days post progression (5 years)</time_frame>
    <description>Patient's health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by PD-L1 expression</measure>
    <time_frame>Up to disease progression or death due to any cause, whichever occurs first (5 years)</time_frame>
    <description>PFS analysis will be performed by PD-L1 subgroup (positive, negative) where a positive status is defined as having ≥ 1% expression and a negative status is defined as having &lt; 1% expression.
Additionally PD-L1 subgroups will also be assessed using defined by a PD-L1 expression level cut-off of 10%, where a positive status is defined as having ≥ 10% expression and a negative status is defined as having &lt; 10% expression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS by PD-L1 expression</measure>
    <time_frame>Up to disease progression or death due to any cause, whichever occurs first (5 years)</time_frame>
    <description>OS analysis will be performed by PD-L1 subgroup (positive, negative) where a positive status is defined as having ≥ 1% expression and a negative status is defined as having &lt; 1% expression.
Additionally PD-L1 subgroups will also be assessed using defined by a PD-L1 expression level cut-off of 10%, where a positive status is defined as having ≥ 10% expression and a negative status is defined as having &lt; 10% expression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">538</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Investigational treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Safety run-in Up to 18 evaluable patients with previously untreated unresectable or metastatic BRAF V600 mutated melanoma will be enrolled and treated at different dose levels to determine the recommended Phase 3 regimen of PDR001 in combination with dabrafenib and trametinib.
Part 2: Biomarker cohort Approximately 20 patients with previously unresectable or metastatic BRAF V600 mutated melanoma will be enrolled to describe changes in the immune microenvironment and biomarker modulations
Part 3: Randomized double blind Approximately 500 patients with previously untreated unresectable and metastatic BRAF V600 mutated melanoma will be enrolled to compare the anti-tumor activity of PDR001 in combination with dabrafenib and trametinib versus placebo plus dabrafenib and trametinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo in combination with dabrafenib and trametinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001 will be supplied in vial in liquid or lyophilized pharmaceutical form. PDR001 will be administered via intravenous infusion over 30 minutes (up to 2 hours) once every 4 or 8 weeks.</description>
    <arm_group_label>Investigational treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be a Dextrose 5% in water (D5W) infusion supplied by the site.</description>
    <arm_group_label>Placebo comparator arm</arm_group_label>
    <other_name>Placebo control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-28 of a 28-day cycle.</description>
    <arm_group_label>Investigational treatment arm</arm_group_label>
    <arm_group_label>Placebo comparator arm</arm_group_label>
    <other_name>Tafinlar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-28 of a 28-day cycle.</description>
    <arm_group_label>Investigational treatment arm</arm_group_label>
    <arm_group_label>Placebo comparator arm</arm_group_label>
    <other_name>Mekinist®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria Part 1: Safety run-in

          -  Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation

          -  Aspartate transaminase (AST) &lt; 2.5× ULN and Alanine transaminase (ALT) &lt; 2.5× ULN

          -  ECOG performance status ≤ 1

        Part 2: Biomarker cohort

          -  Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation

          -  At least two cutaneous or subcutaneous or nodal lesions for tumor sample collection

          -  ECOG performance status ≤ 2

        Part 3: Double-blind, randomized, placebo-controlled part

          -  Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation

          -  ECOG performance status ≤ 2

        Exclusion Criteria:

        Part 1: Safety run-in

          -  Subjects with uveal or mucosal melanoma

          -  Any history of CNS metastases

          -  Prior systemic anti-cancer treatment for unresectable or metastatic melanoma

          -  Prior loco-regional treatment for unresectable or metastatic melanoma in the last 6
             month

          -  Prior neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months

          -  Radiation therapy within 4 weeks prior to start of study treatment

          -  Active, known, suspected or a documented history of autoimmune disease

        Parts 2 &amp; 3: Biomarker cohort &amp; double-blind, randomized, placebo-controlled part

          -  Subjects with uveal or mucosal melanoma

          -  Clinically active cerebral melanoma metastasis

          -  Prior systemic anti-cancer treatment for unresectable or metastatic melanoma

          -  Prior loco-regional treatment for unresectable or metastatic melanoma in the last 6
             month

          -  Prior neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months

          -  Radiation therapy within 4 weeks prior to start of study treatment

          -  Active, known, suspected or a documented history of autoimmune disease

        Other protocol-defined Inclusion/Exclusion may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>November 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDR001</keyword>
  <keyword>dabrafenib</keyword>
  <keyword>trametinib</keyword>
  <keyword>melanoma</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>PD 1 inhibitor</keyword>
  <keyword>anti PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>anti-PD-1</keyword>
  <keyword>combination treatment</keyword>
  <keyword>malignant skin cancer</keyword>
  <keyword>skin cancer</keyword>
  <keyword>BRAF V600</keyword>
  <keyword>unresectable BRAF V600 mutated melanoma</keyword>
  <keyword>metastatic BRAF V600 mutated melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
